Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Cancer Res. 2013 Jun 4;73(15):4885–4897. doi: 10.1158/0008-5472.CAN-12-4081

Table 2.

Patient, Primary Tumor, and Xenograft Characteristics

Patient Xenograft
Line(s)		 Xenograft
PAM50
Intrinsic
Subtype		 Transplant
Condition		 Patient
Ethnicity		 Tumor Source
and Treatment
Status		 Patient Tumor
Type		 Estrogen
Receptor
Status		 Progest-erone
Receptor
Status		 HER2
Status		 BRCA
Status		 Patient
Nodal
Status		 Patient
Metastatic
Site(s)		 Xenograft
Metastasis Rate
To Mouse Lung
(%)		 Patient Clinical
Treatment(s)		 Patient Clinical Response
1 BCM-2147 Basal 1 AA Pre, P.Br rIDC − − − + Brain 0 AC Res
BCM-2277 Basal 1 Post, P.Br − − − 0
2 BCM-2665 Basal 3 Hispanic Post, P.Br IDC, Mpap - − − − 7.1 AC, Doc AC Sen, Doc. Res
3 BCM-3107 Basal 2 Caucasian Post, P.Br IDC − − − − 0 Doc Sen
4 BCM-3143 Basal 2 Caucasian Post wk6, P.Br IDC − − + − 0 Lap −> Taxane + Trastuz Lap Res; Taxane + Trastuz Res
BCM-3104 Basal 2 Post wk4, P.Br + 0
5 BCM-3204 Basal 2 Caucasian Pre, P.Br IDC 28.6 AC Res
6 BCM-3611 Basal 2 AA Pre, P.Br IDC − − − + 0 AC + GSI −> Doc + GSI AC + GSI Res; Doc + GSI Res
BCM-3824 Basal 2 Post, P.Br − − − 0
7 BCM-3887 Basal 2 AA Pre, CWR IDC − − − BRCA1 − Brain 14.3 Xeloda (5FU) Res
8 BCM-3936 Basal 2 Hispanic Post, P.Br IDC − − − + 9.1 AC Sen
9 BCM-3807 Basal 2 Hispanic Pre, P.Br IDC − − − − 0 AC −> Doc + GSI AC Res; Doc + GSI Res
BCM-4400 Basal 2 Post, P.Br − − − 0
10 BCM-3904 Basal 2 Hispanic Pre, P.Br IDC − − − − 18.2 Doc Res
11 BCM-4175 HER2 4 Hispanic Post, P.Br IDC − − − − 0 Das −> AC Res
12 BCM-3963 HER2 2 Hispanic Pre, P.Br IDC − − + + Brain 13.6 Lap + Trastuz Sen
BCM-4169 HER2 4 Post, P.Br − − + 8.3
13 BCM-4195 Basal 4 Hispanic Post, P.Br IDC − − − − 0 Das −> Doc Das Res; Doc Res
14 BCM-4013 Basal 4 Caucasian Pre, P.Br IDC − − − + 21.4 Das + Doc Res
15 BCM-4272 Basal 2 Hispanic Pre, P.Br IDC − − − + 28.6 GSI + Doc Sen
BCM-4849 Basal 2 Post, P.Br − − − 0
16 BCM-4664 Basal 2 AA Pre, P.Br IDC − − − + 0 Das + Doc Res
17 BCM-4913 Basal 2 AA Post wk4, P.Br IDC − − − BRCA1 + 0 Doc Res
BCM-5438 Basal 2 Post, P.Br − − − 0
18 BCM-4888 HER2 4 Hispanic Post, P.Br IDC, Mpap + + + + 66.7 AC −−> GSI + Doc AC Res; GSI + Doc Sen
19 BCM-5097 Basal 2 Caucasian Post, P.Br IDC + + − BRCA2 + 36.4 Doc Sen
20 BCM-5156 Basal 2 Hispanic Post, P.Br IDC − − − nr 0 GSI + Doc Sen
21 BCM-5471 Basal 2 Hispanic Post, P.Br IDC − − − + 33.3 GSI + Doc Sen
22 BCM-5998 Basal 4 Caucasian Pre, CWR IDC − − − nr 0 AC Res
23 BCM-3613 HER2 2 Hispanic Plural fluid Met. − − + nr Brain 23.8 AC, Pac, Traztuz, Lap,
GSI + Doc, Others		 AC Res; Pac Res; Trastuz Res;
Lap Res; GSI + Tax Res
24 BCM-3561 HER2 2 Caucasian Ascites Met. (ER+PR+
primary)		 − − − 0 Xeloda (5FU), Pac. Others Xeloda Res; Pac Res
25 BCM-4189 HER2 2 Hispanic Ascites Met. (LCIS
primary)		 + − − nr 0 AC, Pac, Xeloda,
Arimidex, Faslodex		 AC Res; Pac Res; Xeloda Res;
Arimidex Res; Faslodex Res

Pre, pre-treatment; Post, post-treatment; P.Br, primary breast; CWR, chest wall recurrence; IDC, invasive ductal carcinoma; LCIS, lobular carcinoma in situ; Mpap, micropapillary; Met, metastatic disease; AC, doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) ; Doc, Docetaxel; Pac, Paclitaxel Lap, Lapatinib; Trastuz, Trastuzumab; GSI, gamma secretase inhibitor; Das, Dasatinib; Sen, ≥ 30% response; Res, < 30% response; AA, African American; nd, not determined; nr, not reported